Venetoclax

Building on top-line progression-free survival (PFS) results reported in April, Eli Lilly said Monday that its non-covalent BTK inhibitor Jaypirca (pirtobrutinib) reduced the risk of disease progression or death by almost half in patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL)."These results from BRUIN CLL-322 show that the addition of [Jaypirca] as part of a time-limited regimen further enhanced an already effective treatment and extended the duration of remission for patients with previously treated CLL," said lead author Matthew Davids. "Importantly, the study provides the first robust evidence for such an approach in patients who received a prior BTK inhibitor."The Phase III study enrolled 639 patients, most of whom had prior exposure to covalent BTK inhibitors. Participants were randomly assigned to receive Jaypirca added to venetoclax plus rituximab, or venetoclax plus rituximab alone. Treatment in both study arms was given for up to two years, after which patients do not take any CLL therapy until their disease progresses.According to results presented over the weekend at the European Hematology Association (EHA) annual meeting, the Jaypirca combination was associated with a PFS of 45% compared with venetoclax and rituximab alone. Median PFS in the combination arm was not reached versus 39.7 months controls, with consistent PFS benefits observed across prespecified subgroups."In the context of the modern CLL treatment landscape, where many patients may only receive two lines of therapy, these results speak to the potential benefits that improving second-line therapy can have," Davids added.While overall survival (OS) data remained immature at the time of analysis, Lilly said a key secondary goal of time to next treatment "consistently favoured" the Jaypirca arm, yielding a hazard ratio of 0.5. Final testing of OS superiority is planned at a future date."These data further strengthen…evidence for Jaypirca across the CLL continuum, from monotherapy to combination therapy and across multiple settings," said Jacob Van Naarden, president of Lilly Oncology. The drug holds FDA approvals in previously treated CLL/SLL following a covalent BTK inhibitor and in later-line mantle cell lymphoma.

Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed AML 32 AML patients dosed across 40 mg, 80 mg, 120 mg and 160 mg TUS with TUS+VEN+AZA triplet Composite complete response (CRc) rate in evaluable patients across all dosing groups was 86.2% MRD-negativity in patients who achieved a CR/CRh response was 86.4% AML patients with diverse genetics, including TP53 -mutated, complex karyotypes, and unmutated FLT3, safely achieved responses and MRD negativity SAN DIEGO and TORONTO, June 15, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company, announced that data from its Phase 1/2 TUSCANY trial in newly diagnosed AML patients treated with tuspetinib (TUS) in combination with standard of care dosing venetoclax and azacitidine (TUS+VEN+AZA triplet) was presented yesterday in an oral presentation at the European Hematology Association Congress (EHA 2026) in Stockholm, Sweden. The TUS+VEN+AZA triplet is being developed as a mutation agnostic frontline therapy to treat large, mutationally unrestricted and diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy. Nikolai Podoltsev, MD, PhD, Associate Professor Medical Oncology & Hematology, Clinical Director, Malignant Hematology, Yale School of Medicine, and an investigator in the TUSCANY study, reported updated safety and efficacy data from the 80 mg and 120 mg dose cohorts, as well as new data from the 160 mg dose of TUS in the TUS+VEN+AZA triplet. “While there have been recent successes with targeted therapy in AML treatment, our multi-targeted approach with tuspetinib in combination is showing significant efficacy across mutations that have been historically difficult to treat, including TP53 mutations, where we thus far have achieved CRs in all of the four subjects at the highest dose cohort,” said Rafael Bejar, MD, PhD, Chief Medical Officer, Aptose. “As a safe and effective inhibitor of multiple growth factor signaling pathways, the TUS+VEN+AZA triplet is a first line combination therapy with the potential to improve outcomes in nearly all AML populations.” The oral presentation at EHA included updated safety, complete remission, minimal residual disease (MRD) assessments, and longer duration of follow-up: Presentation title: TUSCANY Study of Safety and Efficacy of Tuspetinib Plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy Presenter: Nikolai Podoltsev, MD, PhD, Associate Professor (Medical Oncology & Hematology), Department of Internal Medicine; Clinical Director, Malignant Hematology, Associate Program Director, Hematology / Medical Oncology Fellowship Program, Yale School of Medicine Key findings: 32 (29 response evaluable), newly diagnosed AML patients have received the TUS+VEN+AZA combination: 4 received the 40 mg dose of TUS, 12 received the 80 mg dose of TUS, 3 received the 120 mg dose of TUS, and 13 received the 160 mg dose The overall CRc rate across dose levels in response evaluable (29) patients was 86.2%. The MRD negative rate among all patients dosed was 62.5%; MRD negative rate in CR/CRh patients was 86.2%. At the 160 mg TUS dose level (n=13): The overall CRc rate was 76.9% (10 of 13 patients), including 8 of 11 (72.7%) with unmutated (or wildtype) FLT3 100 % composite complete remission in all 4 patients with TP53 -mutation with complex karyotype ( TP53 -mut/CK) Regardless of mutation status, TUS is active in newly diagnosed AML patients MRD-negative responses achieved across diverse genetic populations, including adverse TP53 mutations and CK Responses continue to evolve with 19 subjects remaining on treatment, including 6 that moved on to stem cell transplantation TUS can be administered safely with standard-of-care dosing of VEN/AZA TUS PK properties were not significantly altered by VEN, AZA, antifungals or food No treatment-related deaths No treatment-related adverse events of QT c prolongation, CPK elevations or differentiation syndrome Abstracts are available on the EHA2026 website here . The presentation is available on the Aptose website here . TUSCANY: TUS+VEN+AZA Triplet Phase 1/2 Study The tuspetinib-based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 clinical study with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated. Earlier APTIVATE trials of TUS as a single agent and in combination as TUS+VEN demonstrated favorable safety and broad activity in diverse relapsed or refractory (R/R) AML populations that went beyond the more prognostically favorable NPM1 and IDH mutant subgroups. Indeed, responses were also in R/R AML patients with highly adverse TP53 and RAS mutations, and those with mutated or unmutated (wildtype) FLT3 genes. The TUSCANY Phase 1/2 study, being conducted at 10 leading U.S. clinical sites by elite clinical investigators, is designed to test various doses and schedules of TUS in combination with standard dosing of AZA and VEN for patients with AML who are ineligible to receive induction chemotherapy. A convenient, once daily oral agent, TUS, is being administered in 28-day cycles. More information on the TUSCANY Phase 1/2 study can be found on ( here ). About Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company’s lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit Forward Looking Statements This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements relating to the therapeutic potential and safety pro tuspetinib (including the triplet therapy) and its clinical development, as well as statements relating to the Company’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “should”, “would”, “may”, and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to obtain the capital required for research and operations and to continue as a going concern; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities; unexpected manufacturing defects; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States SecuritExchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. For further information, please contact: Aptose Biosciences Inc. Susan Pietropaolo Corporate Communications & Investor Relations 201-923-2049 spietropaolo@aptose.com